

## Supplementary Online Content

Cocchi E, Bloise S, Lorefice A, et al. Nirsevimab prophylaxis and respiratory syncytial virus hospitalizations among infants. *JAMA Netw Open*. 2025;8(11):e2544679.  
doi:10.1001/jamanetworkopen.2025.44679

**eFigure.** Proportional-Hazards Diagnostics (Schoenfeld Residuals) for the Primary Multivariate Cox Model

This supplementary material has been provided by the authors to give readers additional information about their work.

**eFigure. Proportional-hazards diagnostics (Schoenfeld residuals) for the primary multivariate Cox model.**

Panels show scaled Schoenfeld residuals plotted against analysis time (days from birth-discharge) for each covariate in the model. Points are individual residuals; the solid line is a loess smooth; dashed lines are  $\pm 2$  SE (pointwise 95% bands). A horizontal line at zero indicates the proportional-hazards (PH) expectation; systematic departures suggest time-varying associations.

PH tests: nirsevimab  $p=0.065$ , preterm  $p=0.418$ , older siblings  $p=0.074$ , male sex  $p=0.987$ , nirsevimab $\times$ preterm  $p=0.929$ ; global  $p=0.084$ .

No statistically significant departure from proportional hazards overall. Minor drifts for nirsevimab and older siblings are near-threshold but remain small and within uncertainty bands, indicating no material non-proportionality.

